Breast Cancer Diagnostics Market (By Type: Imaging, Biopsy, Genomic Tests, Blood Tests, and Others; By Product: Platform-based Products and Instrument-based Products; By Application: Screening, Diagnostic and Predictive, Prognostic, Research; By End Use: Hospitals & Clinics, Diagnostic Centers & Medical Laboratories, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023 – 2032
The global breast cancer diagnostics market size was estimated at US$ 4.40 billion in 2022 and is expected to reach over US$ 8.70 billion by 2032, poised to grow at a CAGR of 7.10% from 2023 to 2032.
Access our Healthcare Data Intelligence Tool with 10000+ Database, Visit: Towards Healthcare
The U.S. breast cancer diagnostics market size was valued at US$ 1.39 billion in 2022 and is predicted to expand over US$ 2.71 billion by 2032, at a CAGR of 7% from 2023 to 2032.
North America dominated the breast cancer diagnostics market in 2022. The presence of large players, well-established diagnostic and screening infrastructure, technological breakthroughs, strong patient awareness, and attractive reimbursement policies are all elements that contribute to the region’s dominance.
Asia-Pacific, on the other hand, is expected to develop at the fastest rate during the forecast period, as a result of the rising incidence of breast cancer and the use of better diagnostic procedures. Furthermore, the breast cancer diagnostics market expansion is likely to be supported by increasing reimbursement guidelines and expanding healthcare infrastructure.
In the glandular tissue of the breast, breast cancer develops in the living cells of the ducts or lobules. The malignant development is initially restricted to the duct or lobule, where it usually causes no symptoms and has a low risk of spreading.
The treatment for breast cancer can be quite effective, especially if the disease is detected early. The microscopic cancer that has spread from the breast tumor through the blood is generally treated with a combination of surgical removal, medication, and radiation therapy. This type of treatment, which can stop cancer from spreading and growing, save lives.
According to World Health Organization (WHO), breast cancer has affected 2.3 million women worldwide in 2020, with 6,85,000 fatalities. Breast cancer has been diagnosed in 7.8 million women in the previous 5 years as of the end of 2020, making it the most common cancer in the world. Thus, the rising prevalence of breast cancer is driving the growth of the global breast cancer diagnostics market during the forecast period.
Breast cancer tumors are one of the most difficult to diagnose and cure because they are usually discovered after they have progressed to an advanced stage. People are looking for more efficient diagnostic options to deal with the condition effectively; hence demand for early diagnosis of breast cancer is on the rise. Imaging and screening, in addition to other tests for detecting breast cancer, have seen a significant increase in popularity. Although breast cancer screening is thought to be helpful, several approaches are still being contested as to whether they are safe and accurate for long term use.
The most well-known and extensively utilized method is imaging. Due to lack of data to support their reliability, affordability, accuracy, the demand for genomic testing, next generation sequencing, and blood tests in breast cancer diagnosis is very low compared to imaging. Breast biopsy for breast cancer diagnosis is expected to grow in popularity steadily over the forecast period.
The demand for early breast cancer diagnostics in developed nations is increasing due to an increase in cancer cases. A major aspect affecting demand for breast cancer diagnostics in developing nations is the development of inexpensive and cost-effective diagnostic options.
Thus, the rising number of patients with breast cancer and breast-related disorders, the growing number of breast cancer screening programs, the prevalence of favorable government reimbursement policies, and the growth in the number of private diagnostic centers are all expected to boost the global breast cancer diagnostics market during the forecast period.
| Report Coverage | Details |
| Market Size | US$ 8.70 Billion by 2032 |
| Growth Rate | CAGR of 7.10% from 2023 to 2032 |
| Largest Market | North America |
| Fastest Growing Market | Asia Pacific |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | Product, End Use, Application, Region |
| Companies Mentioned | Genomic Health, NanoString Technologies Inc., Paragon Biosciences LLC, Devicor Medical Products Inc., AstraZeneca, Quest Diagnostics Incorporated, Koninklijke Philips N.V., Siemens AG, Biocept Inc., Epigenomics Inc. |
The instrument-based products had the highest revenue share in 2022. For widespread population-based screening of breast cancer patients, imaging is the first approach. All women with breast cancer undergoes a biopsy to confirm their diagnosis of the treatment.
The platform-based products segment is fastest growing segment of the breast cancer diagnostics market in 2020. Due to the increased demand of such products for targeted therapy, the platform-based products segment is expected to develop at the quickest rate throughout the projection period. The next generation sequencing, polymerase chain reaction, and other technologies are used to diagnose breast cancer.
The imaging had the highest revenue share in 2022. The segment is expected to be driven by factors such as ease of access, high number of operations, and increased effectiveness. The ultrasounds, mammograms, and magnetic resonance imaging are the most common imaging methods used for screening and diagnosis.
The blood tests segment is fastest growing segment of the breast cancer diagnostics market in 2020, as a result of a number of research projects being conducted globally by research groups and key players. The liquid biopsy tests’ excellent efficacy is predicted to propel the blood testing segment growth.
The diagnostics and predictive segment dominated the breast cancer diagnostics market in 2022. The rising popularity of genetic testing may contribute to the expansion of the segment.
The prognostic segment, on the other hand, is predicted to develop at a rapid rate over the projection period. As these tests are used to match patients with medicines, they are booming increasingly significant. As a result, the patient’s chances of survival improve dramatically.
In 2022, the hospitals and clinics segment dominated the breast cancer diagnostics market. The segment’s expansion is likely to be fueled by rising patient hospitalizations and the growing burden of disease. The patients undergo biopsies for confirmation testing in hospitals after the screening test.
The diagnostic centers and medical laboratories segment, on the other hand, is predicted to develop at the quickest rate in the future years, as a result of an increase in the number of government programs to provide various services, such as diagnostic test reimbursement.
Key Developments
To strengthen their product portfolio, the major market players use organic and inorganic expansion tactics. To stay competitive in the global breast cancer diagnostics market, these companies have used methods such as geographic growth, collaborations, acquisitions, investment in research and development, and manufacturing of novel breast cancer diagnostic tools in the market.
Segments Covered in the Report
By Type
By Product
By Application
By End Use
By Geography
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Breast Cancer Diagnostics Market
5.1. COVID-19 Landscape: Breast Cancer Diagnostics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Breast Cancer Diagnostics Market, By Product
8.1. Breast Cancer Diagnostics Market, by Product Type, 2023-2032
8.1.1. Platform-based Products
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Instrument-based Products
8.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Breast Cancer Diagnostics Market, By Type
9.1. Breast Cancer Diagnostics Market, by Type, 2023-2032
9.1.1. Imaging
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Biopsy
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Genomic Tests
9.1.3.1. Market Revenue and Forecast (2020-2032)
9.1.4. Blood Tests
9.1.4.1. Market Revenue and Forecast (2020-2032)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Breast Cancer Diagnostics Market, By Application Type
10.1. Breast Cancer Diagnostics Market, by Application Type, 2023-2032
10.1.1. Screening
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Diagnostic and Predictive
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Prognostic
10.1.3.1. Market Revenue and Forecast (2020-2032)
10.1.4. Others
10.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Breast Cancer Diagnostics Market, By End Use Type
11.1. Breast Cancer Diagnostics Market, by End Use Type, 2023-2032
11.1.1. Hospitals & Clinics
11.1.1.1. Market Revenue and Forecast (2020-2032)
11.1.2. Diagnostic Centers & Medical Laboratories
11.1.2.1. Market Revenue and Forecast (2020-2032)
11.1.3. Others
11.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 12. Global Breast Cancer Diagnostics Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Product (2020-2032)
12.1.2. Market Revenue and Forecast, by Type (2020-2032)
12.1.3. Market Revenue and Forecast, by Application Type (2020-2032)
12.1.4. Market Revenue and Forecast, by End Use Type (2020-2032)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Product (2020-2032)
12.1.5.2. Market Revenue and Forecast, by Type (2020-2032)
12.1.5.3. Market Revenue and Forecast, by Application Type (2020-2032)
12.1.5.4. Market Revenue and Forecast, by End Use Type (2020-2032)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Product (2020-2032)
12.1.6.2. Market Revenue and Forecast, by Type (2020-2032)
12.1.6.3. Market Revenue and Forecast, by Application Type (2020-2032)
12.1.6.4. Market Revenue and Forecast, by End Use Type (2020-2032)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Product (2020-2032)
12.2.2. Market Revenue and Forecast, by Type (2020-2032)
12.2.3. Market Revenue and Forecast, by Application Type (2020-2032)
12.2.4. Market Revenue and Forecast, by End Use Type (2020-2032)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Product (2020-2032)
12.2.5.2. Market Revenue and Forecast, by Type (2020-2032)
12.2.5.3. Market Revenue and Forecast, by Application Type (2020-2032)
12.2.5.4. Market Revenue and Forecast, by End Use Type (2020-2032)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Product (2020-2032)
12.2.6.2. Market Revenue and Forecast, by Type (2020-2032)
12.2.6.3. Market Revenue and Forecast, by Application Type (2020-2032)
12.2.6.4. Market Revenue and Forecast, by End Use Type (2020-2032)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Product (2020-2032)
12.2.7.2. Market Revenue and Forecast, by Type (2020-2032)
12.2.7.3. Market Revenue and Forecast, by Application Type (2020-2032)
12.2.7.4. Market Revenue and Forecast, by End Use Type (2020-2032)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Product (2020-2032)
12.2.8.2. Market Revenue and Forecast, by Type (2020-2032)
12.2.8.3. Market Revenue and Forecast, by Application Type (2020-2032)
12.2.8.4. Market Revenue and Forecast, by End Use Type (2020-2032)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Product (2020-2032)
12.3.2. Market Revenue and Forecast, by Type (2020-2032)
12.3.3. Market Revenue and Forecast, by Application Type (2020-2032)
12.3.4. Market Revenue and Forecast, by End Use Type (2020-2032)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Product (2020-2032)
12.3.5.2. Market Revenue and Forecast, by Type (2020-2032)
12.3.5.3. Market Revenue and Forecast, by Application Type (2020-2032)
12.3.5.4. Market Revenue and Forecast, by End Use Type (2020-2032)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Product (2020-2032)
12.3.6.2. Market Revenue and Forecast, by Type (2020-2032)
12.3.6.3. Market Revenue and Forecast, by Application Type (2020-2032)
12.3.6.4. Market Revenue and Forecast, by End Use Type (2020-2032)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Product (2020-2032)
12.3.7.2. Market Revenue and Forecast, by Type (2020-2032)
12.3.7.3. Market Revenue and Forecast, by Application Type (2020-2032)
12.3.7.4. Market Revenue and Forecast, by End Use Type (2020-2032)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Product (2020-2032)
12.3.8.2. Market Revenue and Forecast, by Type (2020-2032)
12.3.8.3. Market Revenue and Forecast, by Application Type (2020-2032)
12.3.8.4. Market Revenue and Forecast, by End Use Type (2020-2032)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Product (2020-2032)
12.4.2. Market Revenue and Forecast, by Type (2020-2032)
12.4.3. Market Revenue and Forecast, by Application Type (2020-2032)
12.4.4. Market Revenue and Forecast, by End Use Type (2020-2032)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Product (2020-2032)
12.4.5.2. Market Revenue and Forecast, by Type (2020-2032)
12.4.5.3. Market Revenue and Forecast, by Application Type (2020-2032)
12.4.5.4. Market Revenue and Forecast, by End Use Type (2020-2032)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Product (2020-2032)
12.4.6.2. Market Revenue and Forecast, by Type (2020-2032)
12.4.6.3. Market Revenue and Forecast, by Application Type (2020-2032)
12.4.6.4. Market Revenue and Forecast, by End Use Type (2020-2032)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Product (2020-2032)
12.4.7.2. Market Revenue and Forecast, by Type (2020-2032)
12.4.7.3. Market Revenue and Forecast, by Application Type (2020-2032)
12.4.7.4. Market Revenue and Forecast, by End Use Type (2020-2032)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Product (2020-2032)
12.4.8.2. Market Revenue and Forecast, by Type (2020-2032)
12.4.8.3. Market Revenue and Forecast, by Application Type (2020-2032)
12.4.8.4. Market Revenue and Forecast, by End Use Type (2020-2032)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Product (2020-2032)
12.5.2. Market Revenue and Forecast, by Type (2020-2032)
12.5.3. Market Revenue and Forecast, by Application Type (2020-2032)
12.5.4. Market Revenue and Forecast, by End Use Type (2020-2032)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Product (2020-2032)
12.5.5.2. Market Revenue and Forecast, by Type (2020-2032)
12.5.5.3. Market Revenue and Forecast, by Application Type (2020-2032)
12.5.5.4. Market Revenue and Forecast, by End Use Type (2020-2032)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Product (2020-2032)
12.5.6.2. Market Revenue and Forecast, by Type (2020-2032)
12.5.6.3. Market Revenue and Forecast, by Application Type (2020-2032)
12.5.6.4. Market Revenue and Forecast, by End Use Type (2020-2032)
Chapter 13. Company Profiles
13.1. Genomic Health
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. NanoString Technologies Inc.
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Paragon Biosciences LLC
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Devicor Medical Products Inc.
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. AstraZeneca
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Quest Diagnostics Incorporated
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Koninklijke Philips N.V.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Siemens AG
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Biocept Inc.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Epigenomics Inc.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
